Gritstone bio, Inc. (GRTS)
After hours:
| Previous Close | 0.7464 |
| Open | 0.7500 |
| Bid | 0.7356 x 600 |
| Ask | 0.7622 x 200 |
| Day's Range | 0.7450 - 0.7895 |
| 52 Week Range | 0.6700 - 3.3300 |
| Volume | |
| Avg. Volume | 2,924,141 |
| Market Cap | 84M |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2400 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.83 |
Simply Wall St.Gritstone bio First Quarter 2024 Earnings: Misses Expectations
Gritstone bio ( NASDAQ:GRTS ) First Quarter 2024 Results Key Financial Results Revenue: US$1.74m (down 29% from 1Q...
GlobeNewswireGritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024 -- -- Nature Medicine publication of Phase 1 study of SLATE (off-the-shelf neoantigen vaccine) and AACR-presented improvements to EDGE™ (tumor antigen identification platform that was recently enhanced
- GlobeNewswire
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To acce
